
CANF Stock Forecast & Price Target
CANF Analyst Ratings
Bulls say
Can Fite Biopharma is expected to achieve commercial success with its pipeline of drugs targeting the A3AR, starting with Namodenoson, which has shown promising results in Phase 2b clinical trials and has the potential to treat a variety of diseases including cancer, inflammatory diseases, and liver disorders. The company's current cash position and partnerships with Gebro Holdings and other global partners provide a strong base for continued development and potential licensing opportunities. However, there are risks associated with commercialization, clinical trials, and regulatory approvals, which should be considered. Nevertheless, based on a risk-adjusted net present value analysis, we see a significant potential for future revenues, leading us to maintain a Buy rating on CANF and raising our 12-month price target to $8.00 per ADS.
Bears say
Can Fite Biopharma is facing a negative outlook due to limited durable treatment options in pancreatic cancer and the need for combination immunotherapy in their pipeline product, as well as the lack of visibility and uncertainty surrounding potential strategic relevance. Additionally, the company's partnership opportunities may not lead to successful collaborations, posing a risk to their program.
This aggregate rating is based on analysts' research of Can-Fite BioPharma Ltd. and is not a guaranteed prediction by Public.com or investment advice.
CANF Analyst Forecast & Price Prediction
Start investing in CANF
Order type
Buy in
Order amount
Est. shares
0 shares